Año: 2018
Journal Impact Factor (JIF): 8.7280
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| IMMUNOLOGY | SCIE | 12/158 | Q1 | T1 | D1 |
| ONCOLOGY | SCIE | 19/230 | Q1 | T1 | D1 |
Año: 2018
Journal Citation Indicator (JCI): 1,700
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| IMMUNOLOGY | 16/175 | Q1 | T1 | D1 | 91,14 |
| ONCOLOGY | 22/302 | Q1 | T1 | D1 | 92,88 |
Año:
2018
CiteScore:
9,000
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Pharmacology | 16/301 | Q1 | T1 | D1 |
| Cancer Research | 32/194 | Q1 | T1 | D2 |
| Immunology | 31/198 | Q1 | T1 | D2 |
| Immunology and Allergy | 27/186 | Q1 | T1 | D2 |
| Molecular Medicine | 19/167 | Q1 | T1 | D2 |
| Oncology | 38/323 | Q1 | T1 | D2 |
SJR año:
2018
Factor de Impacto:
3,337
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Cancer Research | 16/241 | Q1 | T1 | D1 |
| Immunology | 19/228 | Q1 | T1 | D1 |
| Immunology and Allergy | 15/217 | Q1 | T1 | D1 |
| Molecular Medicine | 7/179 | Q1 | T1 | D1 |
| Oncology | 20/401 | Q1 | T1 | D1 |
| Pharmacology | 7/343 | Q1 | T1 | D1 |
| Agencia | Código de Proyecto |
|---|---|
| OmniSeq, Inc. (Buffalo, NY) | - |
| # | Autor | Afiliación |
|---|---|---|
| 1 | Roswell Park Cancer Institute; OmniSeq Inc. (United States) | |
| 2 | Pabla, S | OmniSeq Inc. (United States) |
| 3 | Conroy, JM | Roswell Park Cancer Institute; OmniSeq Inc. (United States) |
| 4 | Nesline, MK | OmniSeq Inc. (United States) |
| 5 | Glenn, ST | Roswell Park Cancer Institute; OmniSeq Inc. (United States) |
| 6 | Dressman, D | OmniSeq Inc. (United States) |
| 7 | Papanicolau-Sengos, A | OmniSeq Inc. (United States) |
| 8 | Burgher, B | OmniSeq Inc. (United States) |
| 9 | Andreas, J | OmniSeq Inc. (United States) |
| 10 | Giamo, V | OmniSeq Inc. (United States) |
| 11 | Qin, MC | OmniSeq Inc. (United States) |
| 12 | Wang, YR | OmniSeq Inc. (United States) |
| 13 | Lenzo, FL | OmniSeq Inc. (United States) |
| 14 | Omilian, A | Roswell Park Cancer Institute (United States) |
| 15 | Bshara, W | Roswell Park Cancer Institute (United States) |
| 16 | Zibelman, M | Fox Chase Cancer Center (United States) |
| 17 | Ghatalia, P | Fox Chase Cancer Center (United States) |
| 18 | Dragnev, K | Sin datos () |
| 19 | Shirai, K | Sin datos () |
| 20 | Madden, KG | Sin datos () |
| 21 | Tafe, LJ | Sin datos () |
| 22 | Shah, N | Community Hospital (United States) |
| 23 | Kasuganti, D | Community Hospital (United States) |
| 24 | de la Cruz-Merino, L | Hospital Universitario Virgen Macarena (Spain) |
| 25 | Araujo, I | Hospital Universitario Virgen Macarena (Spain) |
| 26 | Saenger, Y | Columbia University in the City of New York (United States) |
| 27 | Bogardus, M | Columbia University in the City of New York (United States) |
| 28 | Villalona-Calero, M | Baptist Health South Florida (United States) |
| 29 | Diaz, Z | Baptist Health South Florida (United States) |
| 30 | Day, R | University of Pittsburgh (United States) |
| 31 | Eisenberg, M | Laboratory Corporation of America Holdings (United States) |
| 32 | Anderson, SM | Laboratory Corporation of America Holdings (United States) |
| 33 | Puzanov, I | Roswell Park Cancer Institute (United States) |
| 34 | Galluzzi, L | Université de Paris; Weill Cornell Medicine (United States) |
| 35 | Gardner, M | OmniSeq Inc. (United States) |
| 36 | Ernstoff, MS | Roswell Park Cancer Institute (United States) |